R&D How Europe can harness the full potential of biosimilars Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.
Sales & Marketing Tariffs, pharma, and patients: A Q&A with Orr Inbar In order to discuss the current unsettled landscape, and just how tariffs might affect patients, pharmaphorum spoke with Orr Inbar of QuantHealth.
R&D No longer the little fish: How Europe is holding its own thr... It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.
News EC clears first treatment for high-risk smouldering multiple... Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Digital Health Technology Assessment – Challenges and opportunities ... Changes to Health Technology Assessment in Europe offer new opportunities to streamline processes and get innovative treatments to market faster
Digital Sponsored Enabling Digitally Enhanced Care for Rare Diseases in Europe Integrating AI and Connected Care Technologies in Lysosomal Storage Disease Patient Journeys
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.